Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit;Omalizumab als therapeutische alternative beim atopischen ekzem. Bisherige evidenz und potenzieller nutzen

Hautarzt

Volumn 58, Issue 2, 2007, Pages 128-132

  Schmitt, J ^a   Schakel K ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Antibody; Atopic eczema; IgE; Omalizumab; Systemic treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISONE; TACROLIMUS;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL;

ANTIBODIES, MONOCLONAL; ASTHMA; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN E; RECEPTORS, IGE; TREATMENT OUTCOME;

EID: 33847179163     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1280-y     Document Type: Article

References (15)

1. Adelroth E, Rak S, Haahtela T et al. (2000) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106: 253-259
2. Beck LA, Saini S (2006) Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55: 540-541
3. Casale TB, Condemi J, LaForce C et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286: 2956-2967
4. Chang TW (2006) Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Allergy Asthma Proc 27: 7-14
5. Holgate S, Casale T, Wenzel S et al. (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115: 459-465
6. Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53: 338-340
7. Lane JE, Cheyney JM, Lane TN et al. (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54: 68-72
8. Lanier B (2006) Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc 27: 37-42
9. Leynadier F, Doudou O, Gaouar H et al. (2004) Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113: 360-361
10. Lin H, Boesel KM, Griffith DT et al. (2004) Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113: 297-302
11. Maurer D, Fiebiger S, Ebner C et al. (1996) Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 157: 607-616
12. Milgrom H, Fick RB Jr, Su JQ et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966-1973
13. Reich K, Heine A, Hugo S et al. (2001) Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol 167: 6321-6329
14. Schmitt J, Schäkel K, Schmitt NM, Meurer M (2007) Systemic treatment of severe atopic eczema - a systematic review. Acta Derm Venereol 87 (in press)
15. Vigo PG, Girgis KR, Pfuetze BL et al. (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55: 168-170